EyePoint Pharmaceuticals appoints Dr. Reginald J. Sanders to its Board, enhancing its focus on innovative therapeutics for retinal diseases. Dr. Sanders brings extensive experience in ophthalmology and retina research, supporting EyePoint's clinical trials for treatments like DURAVYU for wet AMD and diabetic macular edema.